𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of recombinant leukocyte a interferon (rIFN-αA) in disseminated malignant melanoma

✍ Scribed by Edward T. Creagan; David L. Ahmann; S. J. Green; Harry J. Long; Joseph Rubin; Allan J. Schutt; Zofia E. Dziewanowski

Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
621 KB
Volume
54
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
✍ G. R. C. McLeod; D. B. Thomson; P. Hersey 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

Interferon in combination with vinblasti
Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study
✍ Stein Gundersen; A. Flokkmann 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 2 views

Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (a-IFN) and vinblastine (VBL). The a-IFN was administered subcutaneously daily at an initial dose of 3 X lo6 IU escalating to a maximal dose of 9 X lo6 U daily for the first 10 weeks fol